Human IL13RA2 Stable Cell Line - BaF3

The IL13RA2 gene, located on chromosome Xq23, encodes the interleukin-13 receptor subunit alpha-2, a high-affinity binding protein for IL-13 that lacks a cytoplasmic signaling domain and primarily functions as a decoy receptor rather than a signal mediator. Unlike its counterpart IL13RA1, IL13RA2 binds IL-13 with considerably higher affinity and plays a role in cytokine internalization and clearance. The Human IL13RA2 Stable Cell Line - BaF3 is generated by stably transfecting the full-length human IL13RA2 gene into the murine IL-3-dependent pro-B cell line BaF3. After transfection, the cells are selected for stable expression and maintained in culture medium supplemented with IL-3 or the appropriate cytokine to support proliferation. The resulting cell line provides a homogeneous and reproducible system that constitutively expresses human IL13RA2 on the cell surface, enabling researchers to study receptor-ligand binding kinetics, downstream signaling events, and cellular responses in a controlled setting.

This cell product serves as a versatile tool in both basic research and drug discovery applications. It is particularly valuable for screening and characterizing monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and other therapeutic biologics that target IL13RA2, a receptor known to be highly overexpressed in a range of aggressive tumors including glioblastoma multiforme, pancreatic cancer, breast cancer brain metastases, and certain pediatric central nervous system malignancies. The BaF3-based platform allows researchers to evaluate the specificity, binding affinity, and functional activity of candidate therapeutics through flow cytometry, cell-based binding assays, and proliferation or viability readouts. Furthermore, the cell line can be used in cytotoxicity assays to assess the potency of immune effector mechanisms such as antibody-dependent cellular cytotoxicity or T-cell redirecting therapies. It also supports mechanistic studies exploring the role of IL13RA2 in tumor progression, fibrosis, and immune regulation, serving as a reliable in vitro model for target validation, lead optimization, and preclinical evaluation of novel IL13RA2-directed interventions.